Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial ResultsGlobeNewsWire • 05/09/24
Dianthus Therapeutics to Participate in the Bank of America Securities 2024 Health Care ConferenceGlobeNewsWire • 05/08/24
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 05/03/24
Dianthus Therapeutics Announces Oral Presentation for DNTH103 at the 2024 American Academy of Neurology (AAN) Annual MeetingGlobeNewsWire • 04/11/24
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY2023 Financial ResultsGlobeNewsWire • 03/21/24
Dianthus Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 03/07/24
Dianthus Therapeutics Announces Initiation of Phase 2 MaGic Trial of DNTH103 In Generalized Myasthenia Gravis (gMG)GlobeNewsWire • 02/26/24